HIV

Bio-Rad Laboratories has secured approval from the US Food and Drug Administration (FDA) for its Bio-Rad BioPlex 2200 HIV Ag-Ab assay.

The assay is designed to differentiate between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Specifically, the test assists in the diagnosis of infection with HIV-1 and / or HIV-2, including acute HIV-1 infection in adults, children two years of age and older, as well as in pregnant women.

FDA Center for Biologics Evaluation and Research director Karen Midthun said: "Today’s approval provides healthcare professionals another option for the diagnosis of HIV infections.

"The ability to diagnose HIV infection early and differentiate between types of infection is important in the care of individuals, as both diseases exhibit the same symptoms but progress at different rates."

See Also:

"The ability to diagnose HIV infection early and differentiate between types of infection is important in the care of individuals."

The BioPlex 2200 HIV Ag-Ab assay allows results of antigen and antibody detection to be reported separately, enabling differentiation between acute and established HIV infection respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Intended for use with the BioPlex 2200 System, which was cleared by the FDA in 2004, the assay can also be used to screen organ donors for HIV-1/2 when the blood specimen is collected, while the donor’s heart is still beating.

However, the assay is not approved for use in screening blood or plasma donors, except in urgent situations where legacy licensed blood donor screening tests are unavailable or their use is impractical.

Both the HIV-1 and HIV-2 are similar, but distinct viruses.

The HIV-1 is responsible for majority of HIV infections worldwide, while HIV-2 is found primarily in West Africa, with some cases of the HIV-2 infection also being identified in the US.

Image: A scanning electron micrograph of HIV-1 budding from cultured lymphocyte. Photo: courtesy of C. Goldsmith.